LC–MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma

González, Oskar; Iriarte, Gorka; Rico, Estitxu; Ferreiròs, Nerea; Maguregui, Miren Itxaso; Alonso, Rosa M.; Jiménez, Roberto

doi:10.1016/j.jchromb.2010.07.026

Cited by 65 publications

(47 citation statements)

References 23 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The column was maintained at 40°C and the injection volume was 20 µL. The HPLC method used in this study was described in detail by Gonzalez et al 9 …”

Section: Quantification Of Flv In Rat Plasma By Hplc-lc-ms/ms Detectormentioning

confidence: 99%

Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers

El-Helw¹,

Fahmy²

2015

IJN

View full text Add to dashboard Cite

The aim of this study is to prepare fluvastatin nanostructured lipid carriers (FLV-NLCs) in order to find an innovative way to alleviate FLV-associated disadvantages. The limitations include poor solubility and extensive first-pass metabolism, resulting in low (30%) bioavailability and short elimination half-life (1–3 hours). FLV-NLCs were prepared by hot emulsification–ultrasonication method. Ten runs were created by three-level factorial design (3 2 ) to optimize FLV-NLCs formulation process. In this study, two factors, four responses, and three-level factorial design were endorsed. The studied variables were lipid:oil ratio ( X 1 ) and sonication time ( X 2 ). However, the responses parameter determined the particle size ( Y 1 , nm), entrapment efficiency percent (EE%, Y 2 ), particles zeta potential ( Y 3 ), and 80% of the drug release after 24 hours ( X 4 ). Furthermore, stability and in vivo pharmacokinetics were studied in rats. The optimized consisted formula had an average particle size of 165 nm with 75.32% entrapment efficiency and 85.32% of drug released after 24 hours, demonstrating a sustaining drug release over 24 hours. An in vivo pharmacokinetic study revealed enhanced bioavailability by >2.64-fold, and the mean residence time was longer than that of FLV. We concluded that NLCs could be promising carriers for sustained/prolonged FLV release with enhanced oral bioavailability.

show abstract

“…The column was maintained at 40°C and the injection volume was 20 µL. The HPLC method used in this study was described in detail by Gonzalez et al 9 …”

Section: Quantification Of Flv In Rat Plasma By Hplc-lc-ms/ms Detectormentioning

confidence: 99%

Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers

El-Helw¹,

Fahmy²

2015

IJN

View full text Add to dashboard Cite

show abstract

“…Similarly, several HPLC methods using tandem mass spectroscopy (LC/MS/ MS) have also been reported for analysis of drug in plasma with their high sensitivity [9][10][11] . The two liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS) has been described for the estimation of drugs (from fixed-dose combination) in rat and human plasma [12,13] . HPLC methods attached with photodiode array-fluorescence and ultraviolet-fluorescence detectors for the analysis of drugs in human plasma have also been reported [14][15][16][17] .…”

Section: Several Bioanalytical Methods Have Been Reportedmentioning

confidence: 99%

Statistical Optimization of Extraction Process for the Quantification of Valsartan in Rabbit Plasma by a HPLC Method

Reddy¹

2017

ijps

View full text Add to dashboard Cite

This article describes a high performance liquid chromatography method for determination of valsartan in rabbit plasma. The method was statistically optimized, developed and validated as per United States of Food and Drug Administration guidelines. The solvent deproteination technique was opted for the extraction of valsartan from rabbit plasma. Full factorial design was used for the optimization of an extraction method. The main effect of deproteinating agent, volume of deproteinating agent, speed of centrifugation and time of centrifugation was found to be significant at P<0.0001 on all the responses. After deproteinization, the drug was analysed on a C 18 column using 20 mM ammonium formate:acetonitrile (58:42 v/v) as the mobile phase with a flow rate of 0.9 ml/min. The standard calibration curve was constructed in the concentration range of 75 ng/ml to 4.0 µg/ml and linearity was found to be 0.9989. Losartan was used as the internal standard. The retention time of valsartan and the internal standard was found to be 11.394 and 6.343 min, respectively. No interference peak was perceived. From the accuracy results, the relative error was found between 0.99 and 13.01% and relative standard deviation was between 1.43 and 12.19%. The percent relative standard deviation of intra-day and inter-day precision was found to be less than 15%. Limit of detection and limit of quantitation were found to be 22.00 and 66.67 ng/ml, respectively. From pharmacokinetic applications, the peak plasma concentration (C max ) of valsartan oral suspension was found to be 1092.67±39.62 ng/ml at 0.67±1.24 h. The half-life and area under the curve were found to be 19.92±10.28 h and 8393.35±131.14 ng/ml, respectively. The high performance liquid chromatography method was successfully demonstrated as rapid and sensitive method which can be used as an alternative for the analysis of valsartan in plasma samples.

show abstract

“…Oskar Gonzalez et al(2010) studied validated a simple fast method simultaneous analysis, in human plasma of VAL using high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) with electro-spray ionization (ESI), Separation of analytes and internal standard (pravastatin) was achieved on a Luna C18(2) (150 mm×4.6 mm, 3 m) column using a gradient elution mode with a run time of 15 min, and the mobile phase composition mixture of acetonitrile and water containing 0.01% formic acid and 10 mM ammonium formate at pH 4.1 and Sample extracted by protein precipitation by using acetonitrile [81] Mikaël Lev et al (2009) studied assay method for direct analysis of VAL in human plasma and urine by a direct on-line solid-phase extraction coupled to tandem-mass spectrometry [82].…”

Section: Liquid Chromatography-mass Spectrometric Methodsmentioning

confidence: 99%

A Concise Review on Analytical Profile of Valsartan

Shirkhedkar¹,

Chaudhari²,

Patil³

et al. 2017

Eurasian J Anal Chem

View full text Add to dashboard Cite

Valsartan (VAL) is an orally active angiotensin-II receptor type-I antagonist. VAL is available alone in dosage form as well as multicomponent formulation with various antihypertensive drugs like nifedipine, hydrochlorothiazide, ramipril, amlodipine and nebivolol hydrochloride, for the management of hypertension. The present investigation assesses the various approaches for analysis of VAL in bulk drug as well as formulated products. A concise review represents the compilation and discussion of about more than 90 analytical methods which includes HPLC, HPTLC, capillary electrophoresis, electrochemical methods and UV-Spectrophotometry methods implemented for investigation of VAL in biological matrices, bulk samples and in different dosage formulations. The review describes the percentage utilization of the various approaches for analysis of VAL. The statistical data regarding the utility of these methods for estimation of VAL published during 2001 to 2016 have been included.

show abstract

LC–MS/MS method for the determination of several drugs used in combined cardiovascular therapy in human plasma

Cited by 65 publications

References 23 publications

Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers

Improvement of fluvastatin bioavailability by loading on nanostructured lipid carriers

Statistical Optimization of Extraction Process for the Quantification of Valsartan in Rabbit Plasma by a HPLC Method

A Concise Review on Analytical Profile of Valsartan

Contact Info

Product

Resources

About